Literature DB >> 20576641

Activity of antiandrogens against juvenile and adult Schistosoma mansoni in mice.

Jennifer Keiser1, Mireille Vargas, Jonathan L Vennerstrom.   

Abstract

OBJECTIVES: The antischistosomal properties of the marketed antiandrogens bicalutamide, flutamide, nilutamide and cyproterone acetate were studied both in vivo and in vitro.
METHODS: Schistosoma mansoni-infected mice were treated orally with 50-400 mg/kg of the antiandrogens 3 and 7 weeks post-infection. In addition, three drug combinations of nilutamide and praziquantel (200/100, 100/100 and 100/50 mg/kg) were administered to mice harbouring adult S. mansoni. Drug effects were also monitored in vitro following exposure to antiandrogen concentrations of 1, 10 and 100 microg/mL.
RESULTS: Low total worm burden reductions (5%-37%) and low to moderate female worm burden reductions (13%-75%) were achieved with the antiandrogens in the S. mansoni juvenile infection model. While flutamide and cyproterone acetate lacked activity against adult S. mansoni in vivo, low to moderate total and female worm burden reductions (0%-47%) were observed with bicalutamide. The highest total and female worm burden reductions (85% and 71%, respectively) (P < 0.001) were documented following a single 400 mg/kg dose of nilutamide. Statistically significant total (91%) and female (85%) worm burden reductions were achieved with the combination of nilutamide (200 mg/kg) and praziquantel (100 mg/kg). Schistosomes incubated with 100 microg/mL cyproterone acetate in vitro died after 15 h. Incubation with bicalutamide, nilutamide and flutamide at 100 microg/mL resulted in decreased movement of S. mansoni adults.
CONCLUSIONS: Our data indicate that the hydantoin derivative nilutamide has interesting antischistosomal properties, confirming previous results of schistosomicidal activities of this drug class.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20576641      PMCID: PMC2920177          DOI: 10.1093/jac/dkq233

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

Review 1.  Parasite regulation by host hormones: an old mechanism of host exploitation?

Authors:  Galileo Escobedo; Craig W Roberts; Julio C Carrero; Jorge Morales-Montor
Journal:  Trends Parasitol       Date:  2005-10-19

Review 2.  Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk.

Authors:  Peter Steinmann; Jennifer Keiser; Robert Bos; Marcel Tanner; Jürg Utzinger
Journal:  Lancet Infect Dis       Date:  2006-07       Impact factor: 25.071

Review 3.  In vitro and in vivo trematode models for chemotherapeutic studies.

Authors:  J Keiser
Journal:  Parasitology       Date:  2009-12-07       Impact factor: 3.234

Review 4.  Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.

Authors:  C Mahler; J Verhelst; L Denis
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

Review 5.  Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.

Authors:  R Migliari; G Muscas; M Murru; T Verdacchi; G De Benedetto; M De Angelis
Journal:  Arch Ital Urol Androl       Date:  1999-12

Review 6.  Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs).

Authors:  Wenqing Gao; James T Dalton
Journal:  Drug Discov Today       Date:  2007-02-07       Impact factor: 7.851

7.  Advancing drug innovation for neglected diseases-criteria for lead progression.

Authors:  Solomon Nwaka; Bernadette Ramirez; Reto Brun; Louis Maes; Frank Douglas; Robert Ridley
Journal:  PLoS Negl Trop Dis       Date:  2009-08-25
  7 in total
  9 in total

1.  Isothermal microcalorimetry to study drugs against Schistosoma mansoni.

Authors:  Theresia Manneck; Olivier Braissant; Yolanda Haggenmüller; Jennifer Keiser
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

2.  Antischistosomal versus antiandrogenic properties of aryl hydantoin Ro 13-3978.

Authors:  Chunkai Wang; Qingjie Zhao; Jaeki Min; Sakthivel Muniyan; Mireille Vargas; Xiaofang Wang; Yuxiang Dong; R Kiplin Guy; Ming-Fong Lin; Jennifer Keiser; Jonathan L Vennerstrom
Journal:  Am J Trop Med Hyg       Date:  2014-03-31       Impact factor: 2.345

3.  Efficacy and side effects of praziquantel in the treatment of Schistosomiasis mansoni in schoolchildren in Shesha Kekele Elementary School, Wondo Genet, Southern Ethiopia.

Authors:  Berhanu Erko; Abraham Degarege; Konjit Tadesse; Asnake Mathiwos; Mengistu Legesse
Journal:  Asian Pac J Trop Biomed       Date:  2012-03

4.  Evaluation of Human Liver Microtissues for Drug Screening on Schistosoma mansoni Schistosomula.

Authors:  Flavio C Lombardo; Paolo S Ravaynia; Mario M Modena; Andreas Hierlemann; Jennifer Keiser
Journal:  ACS Infect Dis       Date:  2020-10-26       Impact factor: 5.084

5.  Aryl hydantoin Ro 13-3978, a broad-spectrum antischistosomal.

Authors:  Jennifer Keiser; Gordana Panic; Mireille Vargas; Chunkai Wang; Yuxiang Dong; Nagsen Gautam; Jonathan L Vennerstrom
Journal:  J Antimicrob Chemother       Date:  2015-02-16       Impact factor: 5.790

Review 6.  Repurposing drugs for the treatment and control of helminth infections.

Authors:  Gordana Panic; Urs Duthaler; Benjamin Speich; Jennifer Keiser
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-07-30       Impact factor: 4.077

7.  Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).

Authors:  Chunkai Wang; Qingjie Zhao; Mireille Vargas; Jeremy O Jones; Karen L White; David M Shackleford; Gong Chen; Jessica Saunders; Alice C F Ng; Francis C K Chiu; Yuxiang Dong; Susan A Charman; Jennifer Keiser; Jonathan L Vennerstrom
Journal:  J Med Chem       Date:  2016-11-28       Impact factor: 7.446

Review 8.  Controlling schistosomiasis with praziquantel: How much longer without a viable alternative?

Authors:  Robert Bergquist; Jürg Utzinger; Jennifer Keiser
Journal:  Infect Dis Poverty       Date:  2017-03-28       Impact factor: 4.520

9.  Immunohistochemical Investigations of Treatment with Ro 13-3978, Praziquantel, Oxamniquine, and Mefloquine in Schistosoma mansoni-Infected Mice.

Authors:  Gordana Panic; Marie-Thérèse Ruf; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.